A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Active:	No
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT04546009
Trial Phases:	Phase III	Protocol IDs:	BO41843 (primary) NCI-2020-08420 2020-000119-66
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT04546009

Summary

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will
evaluate the efficacy and safety of giredestrant combined with palbociclib compared with
letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive,
human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or
progressed) or metastatic breast cancer.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.